-
1 Comment
Neuren Pharmaceuticals Limited is currently in a long term uptrend where the price is trading 17.1% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Neuren Pharmaceuticals Limited's total revenue sank by 59.7% to $62K since the same quarter in the previous year.
Its net income has dropped by 51.2% to $-4M since the same quarter in the previous year.
Finally, its free cash flow grew by 23.4% to $-1M since the same quarter in the previous year.
Based on the above factors, Neuren Pharmaceuticals Limited gets an overall score of 3/5.
| Industry | Biotechnology |
|---|---|
| CurrencyCode | AUD |
| Exchange | AU |
| Sector | Healthcare |
| ISIN | NZNEUE0001S8 |
| Beta | 1.58 |
|---|---|
| Dividend Yield | 0.0% |
| Target Price | 13.36 |
| PE Ratio | 8766.67 |
| Market Cap | 2B |
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NEU.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
